Akso Health
AHG
1.21
+0.04
+3.42%
Akso Health
US · AHG
#3226 by market cap
1.21
+0.04
+3.42%
Live - 5344 symbols - heartbeat 246s ago
· 2026-10-07 19:54
After-hours
1.21
0.00%
- Market cap
- 1.04B
- P/E (TTM)i
- -40.33
- P/Bi
- 5.73
- EPSi
- -0.03
- Div yieldi
- 0.00%
- 52W posi
- 29%
Reader sentiment
Are you bullish or bearish on AHG?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 70.94, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -6.40% YoY
Margins
- Gross margin
- -0.08%
- Operating margin
- -28.92%
- Net margin
- -134.99%
Key ratios & quality
- Altman Z-Scorei
- 70.94
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.70M | 6.91M | 0 | 6.00M | 13.18M | 2.41M | 14.78M | 13.83M |
| Gross profit | -- | 6.91M | 0 | 605.13K | 1.27M | 122.13K | -281.53K | -11.32K |
| Selling & admin expenses | 10.88M | 22.30M | 2.09M | 3.06M | 15.54M | 8.76M | 3.64M | 3.99M |
| Research & development | 0 | 1.03M | -- | -- | -- | -- | -- | -- |
| Operating profit | -7.19M | -16.42M | -2.09M | -2.46M | -14.27M | -8.64M | -3.92M | -4.00M |
| Pretax profit | -6.81M | -46.87M | -4.29M | -4.01M | -13.07M | -9.09M | -166.27M | -20.70M |
| Tax | 807.71K | 489.96K | 0 | 92.82K | 17.55K | 24.99K | -30.80M | -1.99M |
| Net profit | 5.53M | -71.20M | -34.83M | -16.85M | -1.25M | -9.52M | -135.47M | -18.72M |
| Basic EPS | 0 | -4 | -2 | -1 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.30 | -4.38 | -2.13 | -0.84 | -0.06 | -0.21 | -0.48 | -0.03 |
| Line item | 2023-09 | 2024-03 | 2024-09 | 2025-03 | 2025-09 | 2026-03 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | -- | -- | -- | -- | -- | -- |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | -- | -- | -- | -- | -- | -- |
| Pretax profit | -- | -- | -- | -- | -- | -- |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -- | -- | -- | -- | -- | -- |
| Basic EPS | -- | -- | -- | -- | -- | -- |
| Diluted EPS | -- | -- | -- | -- | -- | -- |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 97.68M | 52.02M | 30.12M | 62.63M | 20.46M | 142.02M | 196.12M | 189.55M |
| Cash & ST investments | 57.37M | 6.67M | 15.13M | 18.43M | 7.92M | 85.17M | 176.23M | 170.57K |
| Inventory | -- | -- | 0 | 7.80M | 1.69M | 191.20K | 190.24K | 200.14K |
| Total assets | 173.26M | 80.48M | 31.69M | 62.81M | 20.46M | 142.02M | 214.95M | 189.63M |
| Total current liabilities | 26.56M | 12.36M | 14.41M | 50.52M | 11.62M | 3.59M | 13.81M | 8.71M |
| Short-term debt | -- | 740.75K | 10.00M | -- | -- | -- | 40.06K | 373.09K |
| Long-term debt | 20.00M | 20.00M | -- | -- | -- | -- | -- | -- |
| Total liabilities | 46,752,684.00 | 32,375,270.00 | 14,413,971.00 | 50,520,926.00 | 11,620,783.00 | 3,593,923.00 | 15,802,189.00 | 8,711,006.00 |
| Total equity | 126.50M | 48.10M | 17.27M | 12.29M | 8.84M | 138.42M | 199.15M | 180.92M |
| Retained earnings | 69.77M | -1.43M | -36.26M | -53.11M | -54.47M | -63.93M | -198.90M | -217.58M |
| Line item | 2023-09 | 2024-03 | 2024-09 | 2025-03 | 2025-09 | 2026-03 |
|---|---|---|---|---|---|---|
| Total current assets | 16.88M | 142.02M | 100.21M | 196.12M | 18.39M | 189.55M |
| Cash & ST investments | 9.21M | 85.17M | 91.37M | 176.23M | 11.13M | 170.57K |
| Inventory | 1.23M | 191.20K | 196.72K | 190.24K | 193.92K | 200.14K |
| Total assets | 16.88M | 142.02M | 212.95M | 214.95M | 212.04M | 189.63M |
| Total current liabilities | 11.55M | 3.59M | 12.23M | 13.81M | 12.02M | 8.71M |
| Short-term debt | 350.00K | -- | 4.69M | 40.06K | 41.68K | 373.09K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 11,549,145.00 | 3,593,923.00 | 12,298,251.00 | 15,802,189.00 | 13,732,009.00 | 8,711,006.00 |
| Total equity | 5.33M | 138.42M | 200.65M | 199.15M | 198.31M | 180.92M |
| Retained earnings | -57.93M | -63.93M | -64.51M | -198.90M | -200.18M | -217.58M |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -1.73M | -58.28M | 10.06M | -8.63M | -3.25M | 1.35M | 1.18M | -12.79M |
| Depreciation & amortization | 17.23K | 120.52K | -- | -- | 0 | 0 | 2.15M | 2.37M |
| Free cash flow | -1.74M | -58.48M | 10.06M | -8.63M | -3.25M | 1.35M | 1.02M | -188.46M |
| Dividends paid | -19.55M | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -1.32M | -2.67M | 0 | 10.02M | 0 | 139.34M | 195.88M | 0 |
| Ending cash balance | 57.37M | 10.93M | 15.13M | 21.93M | 9.19M | 86.20M | 176.23M | 170.57K |
| Line item | 2023-09 | 2024-03 | 2024-09 | 2025-03 | 2025-09 | 2026-03 |
|---|---|---|---|---|---|---|
| Operating cash flow | -- | -- | -- | -- | -- | -- |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- |
| Free cash flow | -- | -- | -- | -- | -- | -- |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | -- | -- | -- | -- | -- | -- |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 4.15 | -81.55 | -106.55 | -114.03 | -12.95 | -12.86 | -79.99 | -9.83 |
| ROA %i | 3.28 | -56.59 | -63.28 | -40.92 | -3.82 | -11.64 | -75.62 | -9.23 |
| ROIC %i | 3.61 | -64.13 | -69.07 | -109.95 | -12.95 | -12.86 | -79.95 | -9.81 |
| 5-year avg ROE %i | -- | 14.72 | -11.64 | -43.58 | -62.19 | -65.59 | -65.28 | -45.93 |
| EBIT margin %i | 8.31 | -563.34 | -1,647.62 | -252.16 | -99.13 | -376.57 | -26.55 | -28.92 |
| FCF / sales %i | -- | -- | 573.15 | -- | -- | 55.97 | 6.92 | -- |
| Current ratioi | 3.68 | 4.21 | 2.09 | 1.24 | 1.76 | 39.52 | 14.20 | 21.77 |
| Quick ratioi | 3.55 | 3.47 | 2.05 | 0.76 | 1.48 | 23.70 | 13.69 | 0.17 |
| Debt / assetsi | 11.54 | 25.79 | 31.56 | -- | -- | 0.00 | 0.04 | 0.20 |
| LT debt / equityi | 15.81 | 41.61 | -- | -- | -- | -- | 0.02 | 0.00 |
| Interest coveragei | -- | -25.65 | -13.42 | -19.79 | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -32.27 | -32.93 | -- | 17.54 | 23.99 | -- | 35.05 | 1.62 |
| Net income CAGR (3Y) %i | 16.07 | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -51.33 | -- | -- | -48.78 | -- | -- |
| Line item | 2023-09 | 2024-03 | 2024-09 | 2025-03 | 2025-09 | 2026-03 |
|---|---|---|---|---|---|---|
| ROE %i | -74.36 | -12.86 | -6.40 | -79.99 | -68.03 | -9.83 |
| ROA %i | -29.79 | -11.64 | -5.73 | -75.62 | -63.84 | -9.23 |
| ROIC %i | -71.08 | -12.86 | -6.25 | -79.95 | -67.21 | -9.81 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -683.58 | -376.57 | -86.54 | -26.55 | -32.47 | -28.92 |
| FCF / sales %i | -- | 55.97 | -- | 6.92 | -- | -- |
| Current ratioi | 1.46 | 39.52 | 8.19 | 14.20 | 1.53 | 21.77 |
| Quick ratioi | 1.30 | 23.70 | 7.50 | 13.69 | 1.41 | 0.17 |
| Debt / assetsi | 2.07 | 0.00 | 2.23 | 0.04 | 0.03 | 0.20 |
| LT debt / equityi | -- | -- | 0.03 | 0.02 | 0.01 | 0.00 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Single segment100.00%
Region
People's Republic of China100.00%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.